Generic Natesto Availability
Last updated on Jul 9, 2025.
Natesto is a brand name of testosterone, approved by the FDA in the following formulation(s):
NATESTO (testosterone - gel, metered;nasal)
-
Manufacturer: ACERUS
Approval date: May 28, 2014
Strength(s): 5.5MG/0.122GM ACTUATION [RLD]
Is there a generic version of Natesto available?
No. There is currently no therapeutically equivalent version of Natesto available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natesto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
Patent 11,090,312
Issued: August 17, 2021
Inventor(s): Tkachenko; Natalia
Assignee(s): Acerus Biopharma Inc. (Mississauga, CA)The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing the occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone.
Patent expiration dates:
- March 17, 2034✓
- March 17, 2034
More about Natesto (testosterone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Latest FDA alerts (7)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: androgens and anabolic steroids
- Breastfeeding
- En español
Patient resources
Other brands
AndroGel, Xyosted, Jatenzo, Depo-Testosterone, ... +13 more
Professional resources
Other brands
AndroGel, Xyosted, Jatenzo, Depo-Testosterone, ... +12 more
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.